Searching…
LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome of...
2026年3月27日 · LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome …
Detailed FDA approval information for Leukine, including regulatory status, product details, and official drug labeling information.
2024年12月6日 · LEUKINE is indicated for the treatment of adult and pediatric patients 2 years and older who have undergone allogeneic or autologous bone marrow transplantation in whom …
2024年12月15日 · LEUKINE is indicated to increase survival in adult and pediatric patients from birth to 17 years of age acutely exposed to myelosuppressive doses of radiation (Hematopoietic Syndrome …
Commercial-stage cancer biotech company, Partner Therapeutics, Inc. (PTx), announced the recent FDA approval of Leukine for the treatment of adult and pediatric patients acutely exposed to …
1 INDICATIONS AND USAGE LEUKINE is a leukocyte growth factor indicated: To shorten time to neutrophil recovery and to reduce the incidence of severe and life-threatening infections and …
2018年3月30日 · The FDA has approved the use of sargramostim (Leukine) to increase survival in adult and pediatric patients acutely exposed to myelosuppressive doses of radiation, known as …
2018年3月30日 · The Food and Drug Administration (FDA) has approved the use of Leukine (sargramostim; Sanofi Genzyme) to increase survival in children and adults exposed to …
2018年6月6日 · Leukine® (sargramostim) is indicated for the following uses: (i) following induction chemotherapy in older adult patients with acute myelogenous leukemia (AML) to shorten time to...
2018年6月6日 · The FDA approved sargramostim (Leukine) as a treatment for adult and pediatric patients with hematopoietic subsyndrome of acute radiation syndrome (H-ARS), which occurs …
